Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.07.2012 | Kalzium in der kardialen Pathophysiologie

Pharmacology of myocardial calcium-handling

verfasst von: Julia Vogler, MD, Lars Eckardt, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

Disturbed myocardial calcium (Ca+) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure, cardiac hypertrophy, and certain types of tachyarrhythmias. Pharmacologic treatment of these diseases thus focuses on restoring myocardial Ca2+ homeostasis by interacting with Ca2+-dependent signaling pathways. In this article, we review the currently used pharmacologic agents that are able to restore or maintain myocardial Ca2+ homeostasis and their mechanism of action as well as emerging new substances.
Vorheriger Artikel Calcium antagonists in myocardial ischemia/reperfusion—update 2012
Nächster Artikel Odontogene Infektionen – Teil I
Literatur
1.
Endoh M. Mechanism of action of Ca2+ sensitizers–update 2001. Cardiovasc Drugs Ther. 2001;15:397–403.PubMedCrossRef
2.
Frishman WH, Saunders E. beta-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649–53.CrossRef
3.
Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116:35–43.PubMedCrossRef
4.
Chen X, Houser SR. Pharmacology of L-type and T-type calcium channels in the heart. In: Zipes D, Jalife J, editors. Cardiac electrophysiology—from cell to bedside. Philadelphia: Saunders Elsevier; 2009. p. 175–85.
5.
6.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.PubMedCrossRef
7.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.PubMedCrossRef
8.
Hood WB, Dans A, Guyatt GH, Jaeschke R, McMurray J. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2001;3:CD002901.
9.
Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323–38.PubMedCrossRef
10.
Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther. 2007;114:184–97.PubMedCrossRef
11.
Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13–29.PubMedCrossRef
12.
Wagner JA, Weisman HF, Levine JH, Snowman AM, Snyder SH. Differential effects of amiodarone and desethylamiodarone on calcium antagonist receptors. J Cardiovasc Pharmacol. 1990;15:501–7.PubMedCrossRef
13.
Nokin P, Clinet M, Schoenfeld P. Cardiac beta-adrenoceptor modulation by amiodarone. Biochem Pharmacol. 1983;32:2473–7.PubMedCrossRef
14.
Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009;120:636–44.CrossRef
15.
Woosley RL, Funck-Brentano C. Overview of the clinical pharmacology of antiarrhythmic drugs. Am J Cardiol. 1988;61:61A–9A.PubMedCrossRef
16.
Van Der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244–54.PubMedCrossRef
17.
Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A, et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Europace. 2011;13:897–901.PubMedCrossRef
18.
Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, et al. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol. 2010;48:293–301.PubMedCrossRef
19.
Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol. 2009;54:279–86.PubMedCrossRef
20.
Pott C, Steinritz D, Napp A, Bloch W, Schwinger RH, Brixius K. On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects. Wien Med Wochenschr. 2006;156:451–8.PubMedCrossRef
Metadaten
Titel
Pharmacology of myocardial calcium-handling
verfasst von
Julia Vogler, MD
Lars Eckardt, MD
Publikationsdatum
01.07.2012
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0108-x

Weitere Artikel der Ausgabe 13-14/2012

Odontogene Infektionen – Teil I

  • original article

Calcium antagonists in myocardial ischemia/reperfusion—update 2012

  • Kalzium in der kardialen Pathophysiologie

Calcium is omnipresent in the physiology and pathophysiology of heart disease

  • editorial

Calcium handling and ventricular tachyarrhythmias

  • Kalzium in der kardialen Pathophysiologie

Calcium handling in human heart failure—abnormalities and target for therapy

  • Kalzium in der kardialen Pathophysiologie

Calcium handling and atrial fibrillation

  • original article